Drug Search Results
More Filters [+]

Arhalofenate

Alternative Names: arhalofenate, mbx-102
Latest Update: 2022-03-01
Latest Update Note: PubMed Publication

Product Description

Arhalofenate is also purported to have antiinflammatory activity through inhibition of interleukin-1β (IL-1β), as demonstrated in a monosodium urate murine air pouch model. Arhalofenate was first developed as an insulin sensitizer for type 2 diabetes mellitus. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982369/)

Mechanisms of Action: URAT1 Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CymaBay
Company Location: NEWARK CA 94560
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Arhalofenate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Type 2 Diabetes

Phase 2: Gout|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CB102-21425

P2

Completed

Gout

2015-01-01

CB102-21426

P2

Completed

Gout

2014-12-01

M102-21123

P2

Completed

Gout

2012-02-01

M102-21122

P2

Completed

Gout

2011-11-01

Recent News Events